AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1marketreleases

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company’s common stock to institutional or accredited investors.

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Europe Pyridine Industry Analysis Report 2025-2033 | Germany and France Lead with Strong Agricultural and Pharmaceutical Sectors, Green Chemistry Drive Usage in the UK...

The Europe Pyridine Market is set to grow from USD 198.85 million in 2024 to USD 288.21 million by 2033, at a CAGR of 4.21%. This growth is driven by rising demand in agrochemicals, pharmaceuticals, and food industries. Pyridine's versatility in solvents, pesticides, and chemical intermediates bolsters its usage in Europe. Key market drivers include sustainable agriculture and pharmaceutical expansion, particularly in France and Germany. However, challenges like stringent environmental regulations and volatile raw material prices persist. Leading players like Lonza Group and Bayer AG are pivotal in shaping the market. 
The Europe Pyridine Market is set to grow from USD 198.85 million in 2024 to USD 288.21 million by 2033, at a CAGR of 4.21%. This growth is driven by rising demand in agrochemicals, pharmaceuticals, and food industries. Pyridine's versatility in solvents, pesticides, and chemical intermediates bolsters its usage in Europe. Key market drivers include sustainable agriculture and pharmaceutical expansion, particularly in France and Germany. However, challenges like stringent environmental regulations and volatile raw material prices persist. Leading players like Lonza Group and Bayer AG are pivotal in shaping the market.

Electro-Oxidation Market worth $2.1 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The report "Electro-Oxidation Market by Type (Direct Electro-Oxidation, Indirect Electro-Oxidation), Electrode Material (Boron-Doped Diamond (BBD), Lead...

Electro-Oxidation Market worth $2.1 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The report "Electro-Oxidation Market by Type (Direct Electro-Oxidation, Indirect Electro-Oxidation), Electrode Material (Boron-Doped Diamond (BBD), Lead...

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Genomma Lab Internacional Announces Results for the Second Quarter 2025

MEXICO CITY, July 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results...

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day.

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers